Introduction
Cardiovascular disease increases markedly in prevalence with aging, creating a huge economic burden. 1 Cell senescence underlies the aging process, 2 and is characterized by progressive shortening of telomeres. 3 Critical shortening of these protective 'caps' on the ends of linear chromosomes is associated with heart dysfunction and hypertrophy, 4 impaired cardiomyocyte proliferation, and reduced regenerative capacity. 5 The aged heart exhibits abnormal relaxation and/or increased stiffness, 6, 7 along with interstitial fibrosis and cardiomyocyte hypertrophy, increasing the risk of heart failure with preserved ejection fraction (HFpEF). 8 Among rejuvenating strategies tested to date, parabiosis 9 and cellular reprogramming 10 seem promising, but none has addressed age-related heart dysfunction.
Cardiosphere-derived cells (CDCs) are cardiac progenitor cells which can differentiate into the three major cell types present in the heart, that is, cardiomyocytes, endothelial cells, and smooth muscle cells. 11 Despite their progenitor status, CDCs work primarily indirectly 12 (see Supplementary material online, Reference 1). They have been demonstrated to normalize left ventricular relaxation and diastolic pressure while improving survival in young Dahl salt-sensitive rats with hypertensive HFpEF. 13 In this and other preclinical studies,
CDCs mitigated inflammation, fibrosis and oxidative stress in diseased heart tissue. 14, 15 CDCs are also being tested clinically; data available to date indicate that they are safe, and may lead to improvements in post-ischaemic cardiac structure and function indicative of therapeutic regeneration. 16 Based on this, we hypothesized that aged hearts characterized by fibrosis, myocardial hypertrophy, diastolic dysfunction, and chronic inflammation would benefit from therapy with CDCs. To test our hypothesis, we evaluated the effects of CDCs on age-related heart dysfunction and examined the broader rejuvenating potential of CDCs in a well-established rat model of senescence.
Methods Animals and in vivo study protocol
Old Fisher 344 rats (21.8 ± 1.6 month old) were obtained from the National Institute of Aging. Younger Fishe 344 rats (4.1 ± 1.5 month old) were purchased from Envigo, Indianapolis, IN, USA. All F344 lines available in the USA are from the same origin (Columbia University), so share the same genetic background. All animals were studied in accordance with the local guidelines of the Animal Care and Use Committee as published by the National Institute of Health (NIH Publication No. 86-23, revised 1996). Younger animals were used for the characterization of structural and functional changes related to aging. After initial phenotyping with echocardiography and exercise testing, old animals were divided into two groups that were matched prospectively for comparable baseline properties: Twelve rats were treated with CDCs, and 11 rats received phosphate-buffered saline (PBS, i.e. vehicle control). Prior to administration of CDCs or PBS, rats underwent invasive haemodynamic evaluation of left ventricular (LV) pressure and volume and aortic pressure. Old animals were evaluated at baseline and 1 month later by echocardiography, invasive haemodynamics, and exercise treadmill testing for structural and functional changes. Blood samples were collected at the same time points. After 1 month, animals were euthanized and hearts were harvested for further testing.
Isolation, expansion, and injection of cardiosphere-derived cells
Hearts were excised from 31 Sprague-Dawley neonatal rats to produce CDCs, as described. 17 Rats in the CDC group received 1 Â 10 6 passage 2
CDCs resuspended in 100 mL of PBS into the LV cavity with simultaneous aortic clamping (5 rats) or intramyocardially, divided among four injection sites (anterior, lateral, posterior walls and apex (7 rats). The same delivery strategies were used in the control group: intracavitary (LV, 5 rats) and intramyocardial (6 rats). No major differences were observed in the end points, and CDCs' cardiac engraftment is similar (see Supplementary material online, Reference 2) with the two delivery strategies, so pooled results are presented.
Functional, histological, and molecular studies
Detailed descriptions of all the studies are available in the Supplementary Material online.
In vitro studies
When minced human heart tissue is grown in primary culture, it spontaneously gives rise to monolayers of cardiac stromal/progenitor cells (CSPCs). 17 Cardiosphere-derived cells from human donors >55 years of age (old CSPCs) were used to assess human cardiac senescence in vitro. Cardiomyocytes were isolated from old rats (24 months) by enzymatic dissociation of the ventricles as described (see Supplementary material online, Reference 3). Human and rat cells were (separately) targeted with CDCs and exosomes secreted by CDCs or (CDC-XO) obtained from paediatric (<2 years of age) human donors (young CDCs or CDC-XO). For more detailed explanation, see Supplementary Material online.
Statistical analysis
All results are presented as mean ± standard deviation (± SEM in figures) or percentages, for continuous and categorical variables, respectively. Significance of differences was assessed by Student t-test or with one-way Analysis Of Variance (ANOVA) in case of multiple groups if the distribution of the variable was normal; otherwise, the Mann-Whitney or Kruskal-Wallis tests were used. Paired t-test was used to determine significance between baseline and end point in the same group of animals. Age-related changes in three age groups were estimated by linear regression analysis. Based on our previous results ($10 ± 5% of differences in the functional tests between experimental groups), a sample size of 10
Translational perspective
In senescent rats, we tested the idea that treatment with cardiosphere-derived cells 
Results
We first characterized the animal model in terms of age-related structural and functional changes (see Supplementary material online, Figure S1 ). Aging was associated with progressive diastolic dysfunction (see Supplementary material online, Figure S1a -e and n) with preserved systolic function (see Supplementary material online, Figure  S1h , i, and n), and steady increases of LV mass and LV diameter (see Supplementary material online, Figure S1f , g, and n). Blood pressure did not differ significantly among age groups (see Supplementary material online, Figure S1j and n), but exercise capacity decreased with aging (see Supplementary material online, Figure S1m and n).
Functional improvement of the heart: cardiosphere-derived cells decrease stiffness and improve relaxation of the left ventricle Figure 1A shows representative images of transmitral blood flow and tissue Doppler in PBS-and CDC-injected rats. After 1 month, old rats that had been transplanted with CDCs (but not those that had received only PBS) showed a decrease of E/A (from 4.2 ± 1.8 at baseline to 2.1 ± 0.4, P < 0.01) and E/E' ratios (from 22.6 ± 5.2 at baseline to 16.3 ± 4.3, P = 0.05), back towards values seen in young rats ( Figure 1B) . Serial invasive haemodynamic measurements confirmed the echocardiographic findings. Figure 1C shows examples of pressure-volume loops before and 1 month after injection of PBS or CDCs in old animals. Such data were used to derive the slope of the LV end-diastolic pressure-volume relationship (EDPVR). Cardiosphere-derived cell treatment (but not PBS) decreased EDPVR after 1 month ( Figure 1D , upper panel), indicating improved stiffness. The time constant of relaxation Tau ( Figure 1D , lower panel) was abbreviated in CDC-transplanted rats 1 month postinjection (22.2 ± 3.5 ms vs. 26.9 ± 6.0 ms in PBS, P < 0.05, respectively). Minimum dP/dT values showed a similar trend as Tau, but did not reach statistical significance (see Supplementary material online, Figure S2 ).
No significant differences or evolving changes were observed in LV systolic function, which was normal in both groups at baseline (fractional shortening of $38% and ejection fraction of $66%, with no differences in the slope of the end-systolic pressure-volume relationship between groups; see Supplementary material online, Figure S2 ).
Structural changes of the heart: cardiosphere-derived cells regress left ventricular hypertrophy and are associated with less fibrosis Figure 2A shows typical LV M-Mode images before and 1 month after injection of PBS or CDCs. After intervention in old rats, wall thickness decreased in the CDC group (P < 0.01 for interventricular septum and LV posterior wall) with borderline reduction of LV mass ( Figure 2B , see Supplementary material online, Figure S2 ), but PBS injection had no evident effect. The echocardiographic changes were supported by the histological finding of smaller cross-sectional cardiomyocyte area after CDC vs. PBS injection (P < 0.0001, Figure 2C and D). Similar reductions in cardiomyocyte hypertrophy with CDCs have been observed in post-ischaemic heart failure. 18 Additionally, cardiac fibrosis, assayed by Masson's trichrome staining ( Figure 2E and F), was reduced in rats transplanted with CDCs compared with control. Figure 2F shows that overall fractional fibrotic area dropped from 7.3% vs. 4.4% (P < 0.05), an effect which reflected reductions of scar throughout the heart. Finally, serum levels of brain natriuretic peptide (BNP), which is known to rise in human aging, increased with age in our study, but further increases post-injection were blunted by treatment with CDCs ( Figure 2G ).
Cardiosphere-derived cells induce biological rejuvenation of the heart
We analysed the expression of 168 genes implicated in tissue aging and cellular senescence pathways in whole-heart extracts from young rats, and from old rats treated with CDCs or PBS ( Figure 3 ). Comparing the transcriptomes of CDC-and PBS-injected rats, significant differences were detected in 37% of the genes ( Figure 3A and B). Most of the CDC-related changes (85.5%) directionally recapitulated the gene expression patterns of young animals ( Figure 3C ). Among the genes affected, those implicated in cell cycle control (e.g., E2f1 and Rbl1) and immune response (e.g., Fcer1g and Lrf7) figured most prominently ( Figure 3D ).
We found that cardiac telomeres were longer at study end-point in CDC-injected animals (P < 0.0001 vs. PBS controls; Figure 4A and B). About half of cells in the PBS group had extremely short telomeres (within the lowest quartile of length), compared with only 10% in CDC-injected rats ( Figure 4Biii ). In contrast, $40% of heart cells in the CDC group were within the highest quartile of telomere length (compared with <10% in PBS-injected animals). Findings were similar when telomere length was evaluated specifically in cardiomyocytes ( Figure 4C) , with longer mean length in CDC-injected rats (P < 0.0001 vs. PBS, Figure 4Cii ) and an inverse telomere length distribution between the two groups (P < 0.0001, Figure 4Ciii ).
Cardiosphere-derived cells cause favourable systemic effects
As described (see Supplementary material online, Reference 4), aging was associated with a marked decrease of exercise capacity (P < 0.001, see Supplementary material online, Figure S1m ). In the aged rats, treadmill exercise capacity increased by $25% in the month after CDC injection (107.8 ± 25.5 m to 128.6 ± 12.4 m; P < 0.05), but changed little in PBS-injected old animals ( Figure 5A ). Weight loss secondary to sarcopenia or cachexia, compounded by surgery, also appeared to be responsive to CDCs: PBS-injected rats lost $30% more body weight in the post-operative month compared with CDC-transplanted animals (P = 0.05, Figure 5B ). As systemic biomarkers of inflammation, interleukins (IL) 6, and 1b are known components of the senescence-associated secretory phenotype (SASP) which is implicated in propagation of the aging process. 19 Serum levels of these ILs and other inflammatory cytokines were higher in old rats than in young animals (see Supplementary material online, Figure S4A ), but CDC therapy lowered IL-1b and IL-6 levels (by 25% and 60%, respectively) compared with control rats at the study end point ( Figure 5C ). In eight animals, serum samples were available both at baseline and study end point, showing a five-fold decrease of IL-6 levels in CDC-treated rats. Heart and renal functions are closely correlated in the clinical entity of cardio-renal syndrome, 20 which is prominent in elderly patients. Both serum creatinine (sCr) and blood urea nitrogen (BUN) levels were higher in old than in young rats (see Supplementary material online, Figure S4C and D). Levels of sCr decreased in CDC-injected old rats (P < 0.05) over the month post- intervention, despite less body weight loss than in PBS-injected animals. Taken together with the minimal decrease of BUN levels in the CDC group versus an increase in the control rats (see Supplementary material online, Figure S4B ), estimated glomerular filtration rate increased in the CDC-transplanted animals ( Figure 5D ). Also, we observed an unexpected increase in the rate of hair regrowth after shaving in animals that had received CDCs relative to those injected with PBS (Figure 5E and F; see Supplementary material online, Figure S5 ). The improvements in exercise capacity, body mass, inflammatory cytokines, renal function and hair growth reveal that the rejuvenating benefits of CDCs are not limited to, or specific for, the cardiovascular system. Finally, serum levels of GDF 11, proposed as a systemic rejuvenating factor, 9 were comparable in our experimental groups (see Supplementary material online, Figure S6 ), making it unlikely that this molecule plays an important role in CDCassociated rejuvenation.
14.5% CDC≈Y Significantly down-regulated genes in hearts of young and/or old-CDC animals compared with old-PBS group. (C) Diagram showing the proportion of differently-regulated genes (only those with significant differences) in young and/or old-CDC treated rats vs. old-PBS animals (62 genes of a total of 168 analysed). Of those 62 genes, 85.5% of the CDC-related changes recapitulated the gene expression pattern observed in young rats. (D) Genes with significant differences in both young and old-CDC rats vs. old-PBS animals. Ns: young rats (n = 4), old-PBS (n = 7), old-CDC (n = 8). control rats; only cytokines with significant differences between the groups (n = 7 in each group) are presented. (D) Estimated glomerular filtration rate (eGFR) based on serum levels of creatinine (sCr), blood urea nitrogen (BUN) and weight. Although animals in the PBS group lost more weight than rats injected with CDCs, the latter experienced a greater decrease of sCr levels (P = 0.04) and BUN (BUN levels increased in the control rats). These changes translate into a 25% increase of eGFR in CDC-treated animals and an 11% decrease in PBS-injected animals. 
Exosomes as mediators of anti-senescent effects of cardiosphere-derived cells
Our data are consistent with the hypothesis that telomerase activation and related telomere elongation underlie the anti-senescent effects observed here in old rats. We wanted to test this idea, and to do so in human cells in order to exclude rodent-specific effects. To assay the potential anti-aging effects of young CDCs on old human heart cells, we primed CSPCs obtained from >55-year-old donors with young (donors <2 years of age) CDCs, resuspended in serumfree conditioned media, using a transwell co-culture system. Telomerase was almost inactive in old CSPCs but its activity increased four-fold after 96 h of transwell culture with young CDCs, compared with control ( Figure 6A ). Many, if not most, effects of CDCs are mediated by secreted exosomes. A blocker of exosome release, GW4869 (20 uM), abrogated the telomerase-activating effect of CDCs ( Figure 6A) . Furthermore, old CSPCs primed with exosomes isolated from young CDCs (CDC-XO) exhibited a sixfold increase of telomerase activity ( Figure 6A ). Both lines of evidence support the notion that exosomes mediate young CDC-induced telomerase activation.
One of the main functions of telomerase is telomere lengthening with associated cellular rejuvenation. 21 We further tested both effects in old CSPCs. Telomeres were longer ( Figure 6B ) and the number of senescence-associated b-galactosidase positive (SA-GALþ) CSPCs were lower ( Figure 6C ) in young CDC-XO primed cells compared with control cells after 96 h. To investigate whether these effects are seen in working myocardial cells, we tested the effects of young CDC-XO on ventricular cardiomyocytes isolated from old (24 month old) rats (see Supplementary material online, Figure S7 ). The proportion of senescent SA-GALþ cells was lower in CDC-XO-primed cardiomyocytes than in control cells (P < 0.05; see Supplementary material online, Figure S7A ), accompanied by a two-fold increase of borderline statistical significance in telomerase activity after 72 h (see Supplementary material online, Figure S7B ). We analysed short-and long-term survival of a-sarcomeric actinin positive cardiomyocytes and observed a progressive decrease in the number of cells in the control group after 24 h, but preservation of the initial number of plated cardiomyocytes in the CDC-XO-primed group (see Supplementary material online, Figure S7C ). 
Discussion
Here we documented the ability of cell therapy to attenuate agerelated diastolic dysfunction and structural changes. Unexpectedly, we also found broadly favourable systemic effects of CDCs in old animals, despite the fact that the cells were delivered to the heart. The in vivo findings are supported by in vitro demonstration of novel exosome-mediated anti-senescent properties, yielding mechanistic insights into the anti-aging effects of young CDCs (Figure 7 ). Cardiac and vascular aging prominently affect diastolic function. 22 Left ventricular diastolic stiffness increases with normal aging in humans, even in the absence of hypertension, 23 a phenomenon also observed here and previously in aging rats. Longitudinal echocardiographic assessments reveal prominent age-related myocardial hypertrophy. 24 Aging hearts exhibit myocyte hypertrophy, increased myocyte apoptosis, interstitial and subendocardial fibrosis, and amyloid deposition as consequences of multiple senescence-related pathways. 25 Cardiosphere-derived cells increased telomere length, recapitulated a young gene expression pattern, decreased interstitial fibrosis and attenuated hypertrophy. Meanwhile, diastolic function improved, in association with lower levels of circulating BNP in CDC-injected rats.
Telomere shortening is a biomarker of lifetime stress, and telomere attrition is responsible for accelerated aging. 3, 21 Moreover, telomere dysfunction is a popular target for interventions to augment the regenerative capacity of mammalian hearts, given that telomeres figure prominently in cardiomyocyte cell-cycle arrest after birth. 5 Here, telomere length of heart cells globally, and of cardiomyocytes specifically, was greater in old animals transplanted with CDCs obtained from very young rats compared with placebo (PBS). Telomerase is activated in the neonatal mammalian heart 26 and is required for heart regeneration in zebrafish. 27 We found that telomerase activity was increased in old human heart progenitor cells and in senescent rat cardiomyocytes primed with young CDCs. These effects were mediated in a paracrine manner by CDC-secreted exosomes. Telomerase activation was associated with telomere elongation, decreased cell senescence and cardioprotection in culture. Our results indicate that telomere elongation with CDCs is not exclusive to cardiomyocytes. Although non-cardiomyocyte heart cell populations were not specifically characterized in this study, rejuvenation of any type of cell, defined by the presence of longer telomeres, will likely be beneficial from a functional point of view. Specifically, senescence of fibroblasts may contribute to diastolic dysfunction by favouring their transformation into proinflammatory myofibroblasts, with consequent adverse extracellular matrix remodelling and secretion of inflammatory cytokines. 28 Circulating levels of inflammatory cytokines IL-1b and IL-6 were decreased, accompanied by an increase of anti-inflammatory IL-10 levels in old CDC-treated animals. Thus, CDCs antagonize the SASP, which contributes to a spiral of increasing inflammation, dysfunction, and age-related diseases. 29 Attenuation of SASP may underlie the Figure 7 Schematic depiction of heart aging and proposed mechanisms whereby young CDCs exert anti-senescent effects. The process of aging is depicted in the upper row. Transplanted CDCs secrete exosomes (CDC-XO) which lead to cellular rejuvenation. In the heart, left ventricular hypertrophy (LVH) is attenuated and fibrosis is decreased, leading to improved diastolic function. Systemically, a reduction of the senescence-associated secretory phenotype (SASP) contributes to systemic benefits. Although not shown here, we cannot rule out remote effects of CDCs or CDCsecreted exosomes on target tissues, independent of SASP. observed improvements in exercise capacity, sarcopenia, hair regrowth and renal function. The systemic benefits of CDC therapy discovered here, notably the sizable increase of functional capacity, are remarkable in that they transcend mere localized correction of single-organ dysfunction. The marked systemic benefits on hair regrowth, renal function and exercise capacity appear disproportionate to the improvements in cardiac performance. The systemic improvements are all the more striking for having occurred remote from the focused site of delivery of the CDCs into the heart. While we have not explored the mechanism of the remote effects, it is not unreasonable to hypothesize contributions from CDCs that may have leaked into the systemic circulation, and/or secretion of exosomes from embedded CDCs. Systemic spread of exosomes has been implicated in various long-range signalling processes, including the skeletal myopathy that accompanies heart failure. 30 In our scenario, the proposed long-range signalling differs in that it would be salutary rather than detrimental.
Study limitations
Maximum life span in this rat strain is $2.5 years, and we studied $22-month-old animals. Thus, our 1-month follow-up does not suffice to determine if the observed changes are maintained over time, or whether longevity is affected. In addition, extrapolation to humans should be made only cautiously. Although we selected a naturallyaged animal model containing many similarities to normal human aging, 8, 9 we did not consider frequent comorbidities such as hypertension, and associated treatments, which may influence the response to cell therapy. We did, however, confirm that CDCs and their exosomes antagonize human heart cell aging in vitro. Additionally, although all of the functional studies were performed sequentially, allowing us to evaluate CDC-induced changes in the same animal, histopathological evaluation was done only at study end-point, so only differences between groups at that specific time point could be assessed. The detailed specific antifibrotic and antihypertrophic mechanisms were not evaluated, being beyond the scope of this article, but the implication of exosomes does tie in mechanistically to previous work showing exosome-mediated reductions in cardiac fibrosis and hypertrophy. 12, 31 Finally, the design of this study does not establish if the rejuvenating properties shown here are seen only with young CDCs, so the efficacy of adult cells, demonstrated in other studies (see Supplementary material online, References 5 and 6) should be further tested.
Conclusions
The present findings motivate further translational studies of rejuvenation by CDC therapy. If such follow-up studies are promising, progress to clinical testing may be highly feasible, given that allogeneic CDCs are already in advanced clinical testing and have proven safe to date.
